The global human growth hormone market size was valued at USD 6.81 billion in 2024 and is projected to reach from USD 7.63 billion in 2025 to USD 18.75 billion by 2033, growing at a CAGR of 11.90% ...

Global Human Growth Hormone industry is estimated to reach from USD 6.9 Billion in 2024 to USD 13.5 Billion by 2032, driving CAGR of 11.3% The market supports treatment for growth hormone deficiencies ...

For instance, in October 2021, Pfizer, Inc. and OPKO Health, Inc. updated their Biologics License Application to the U.S. FDA for the investigational drug somatropin to treat growth hormone ...

OPKO Health’s weekly growth hormone injection could be approvable in adults without need for further clinical trials, the company has told pharmaphorum. The biotech has worked with Pfizer to co ...

Pfizer's Q4 revenue beats expectations with ... it began last year as it aims to show investors steadier execution and growth after large swings related to its COVID-19 vaccine.

Human Growth Hormone Market Global Human Growth Hormone industry is estimated to reach from USD 6.9 Billion in 2024 to USD 13.5 Billion by 2032, driving CAGR of 11.3% EU, EUROPEAN UNION, UNITED KINGDO ...

For instance, in October 2021, Pfizer, Inc. and OPKO Health, Inc. updated their Biologics License Application to the U.S. FDA for the investigational drug somatropin to treat growth hormone ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Pfizer expressed confidence in sustaining growth across oncology, cardiovascular, and vaccines, backed by strong commercial execution and market share gains. Pfizer reported Q4 2024 revenue of $17 ...